Amedeo Caflisch

Amedeo Caflisch

Auto-generated profile, based on publicly available information

Amedeo Caflisch

University of Zürich

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2018 in Current Opinion in Structural Biology
Verified
Journal Article
Closed access
PŚPaweł Śledź
Paweł Śledź
ACAmedeo Caflisch
Amedeo Caflisch

5 October 2007 in Journal of Computational Chemistry
Verified
Journal Article
Closed access
PDF file
UHUrs Haberthür
Urs Haberthür
ACAmedeo Caflisch
Amedeo Caflisch

1 July 2006 in Journal of Molecular Biology
Verified
Journal Article
Closed access
RPRiccardo Pellarin
Riccardo Pellarin
ACAmedeo Caflisch
Amedeo Caflisch

1 February 2015 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
HZHongtao Zhao
Hongtao Zhao
ACAmedeo Caflisch
Amedeo Caflisch

11 January 2021 in Chemical Reviews
Verified
Journal Article
Closed access
Danilo MilardiDanilo Milardi
Danilo Milardi
EGEhud Gazit
Ehud Gazit
SRSheena E. Radford
Sheena E. Radford
YXYong Xu
Yong Xu
RGRodrigo U. Gallardo
Rodrigo U. Gallardo
Ayyalusamy RamamoorthyAyyalusamy Ramamoorthy
Ayyalusamy Ramamoorthy

8 July 2021 in ChemMedChem
Verified
Journal Article
Open access
PDF file
EMElena V. Moroz‐Omori
Elena V. Moroz‐Omori
DHDanzhi Huang
Danzhi Huang
RBRajiv Kumar Bedi
Rajiv Kumar Bedi
SCSherry J. Cheriyamkunnel
Sherry J. Cheriyamkunnel
EBElena Bochenkova
Elena Bochenkova
ACAmedeo Caflisch
Amedeo Caflisch
The methylase METTL3 is the writer enzyme of the N6‐methyladenosine (m6A) modification of RNA. Using a structure‐based drug discovery approach, we identified a METTL3 inhibitor with potency in a biochemical assay of 280 nM, while its enantiomer is 100 times less active. We observed a dose‐dependent reduction in the m6A methylation level of mRNA in several cell lines treated with the inhibitor already after 16 h of treatment, which lasted for at least 6 days. Importantly, the prolonged incubation (up to 6 days) with the METTL3 inhibitor did not alter levels of other RNA modifications (i. e., m1A, m6Am, m7G), suggesting selectivity of the developed compound towards other RNA methyltransferases.